PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome

Journal of Urology

Volumn 179, Issue 4, 2008, Pages 1587-1592

  Deras, Ina L ^a   Aubin, Sheila M J ^a   Blase, Amy ^a   Day, John R ^a   Koo, Seongjoon ^a   Partin, Alan W ^c   Ellis, William J ^d   Marks, Leonard S ^b   Fradet, Yves ^e   Rittenhouse, Harry ^a   Groskopf, Jack ^a  

^a Gen Probe Incorporated   (United States)

^b Urological Sci Research Foundation   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

biological; diagnosis; human; prostate; prostate cancer antigen 3; prostatic neoplasms; tumor markers

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; RNA; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; ASSAY; CANCER CELL; CANCER DIAGNOSIS; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR BIOPSY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BIOPSY; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; URINE;

EID: 40849087631     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.11.038     Document Type: Article

References (20)

1. Bunting P.S. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 315 (2002) 71
2. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
3. Guinan P., Bhatti R., and Ray P. An evaluation of prostate specific antigen in prostatic cancer. J Urol 137 (1987) 686
4. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909
5. Tchetgen M.B., and Oesterling J.E. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 24 (1997) 283
6. Tricoli J.V., Schoenfeldt M., and Conley B.A. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10 (2004) 3943
7. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542
8. Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521
9. Steuber T., Helo P., and Lilja H. Circulating biomarkers for prostate cancer. World J Urol 25 (2007) 111
10. Hessels D., Klein Gunnewiek J.M., van Oort I., Karthaus H.F., van Leenders G.J., van Balken B., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8
11. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64 (2004) 311
12. Tao Z.H., Mao X.L., Wang C.H., Chen X.D., Yu K.Y., Weng Z.L., et al. Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction. Zhonghua Nan Ke Xue 13 (2007) 130
13. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532
14. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975
15. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695
16. van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13 (2007) 939
17. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089
18. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837
19. Thompson I.M., Bermejo C., Hernandez J., Basler J.A., and Canby-Hagino E. Screening for prostate cancer: opportunities and challenges. Surg Oncol Clin N Am 14 (2005) 747
20. Parekh D.J., Ankerst D.P., Higgins B.A., Hernandez J., Canby-Hagino E., Brand T., et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 68 (2006) 1152